Kornimate/medical-research-clean huggingface dataset:
pots-flow: interplay between gut hormones and autonomic postprandial blood flow regulation in patients with pots

Conditions: Postural Orthostatic Tachycardia Syndrome (POTS); Healthy

Summary: this study will describe the interplay between the gut hormones gip and cck and their regulation of blood flow to the large vessels in patients with postural orthostatic tachycardia syndrome (pots) and gip, cck and glp-1 in healthy. this is addressed by hormone infusions during mr-scans of the abdomen and intake of oral glucose.

each participant will attend independent randomized experimental days with mr-scans during and intravenous infusions of hormones or placebo and ingestion of glucose or water. a continuous intravenous infusion of either gip(3-30)nh2, cck8- or saline for pots-group or gip(3-30)nh2, cck-8, saline or exendin(9-39)nh2 in healthy is started while the participant lie in the scanner while scans, blood samples and questionnaires are repeated over the time course of 2 hours. at a specific timepoint the participants will ingest 75 g of glucose dissolved in 250 ml water.

Eligibility criteria:
inclusion criteria pots patients: * previously diagnosed with pots in tilt test or active stand-test (either newly diagnosed within last 3 months or in new tilt test/active stand test during screenings visit) * reproducible orthostatic intolerance with raise in hr on \>30 bpm when standing within 10 minutes of change of supine to standing in age \>19 years or \>40 bpm in age 18-19 years. * pots symptoms/orthostatic intolerance * age 18-50 * waist ratio \<180 cm exclusion criteria: * chronic illness * metallic implants * above 10 alcoholic drinks or week or substance abuse * other types of sinus tachycardia or heart disease * liverenzymes two times above normal values * decreased kidney function egfr \<90 or elevated kreatinkinasis * thyroid disease or tsh out of reference * uncontrollable low or high blood pressure * blood vessels that cannot be visualized on mr * any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours inclusion criteria: * age 18-50 * waist ratio \<180 cm * matched a pots patient in age, sex and bmi exclusion criteria: * chronic illness * metallic implants * above 10 alcoholic drinks or week or substance abuse * pots; other types of sinus tachycardia or heart disease * liverenzymes two times above normal values * decreased kidney function egfr \<90 or elevated kreatinkinasis * thyroid disease or tsh out of reference * uncontrollable low or high blood pressure, orthostatic hypotension * blood vessels that cannot be visualized on mr * any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours

Keywords: postural orthostatic tachycardia syndrome pots glucose-dependent insulinotropic polypeptide gip glucagon-like peptide-1 glucagon-like peptide-2 glp-1 glp-2 cck-8 cholecystokinin splanchnic blood flow
phase 3 study evaluating safety and efficacy of otx-dp for treatment of ocular inflammation and pain after cataract surgery

Conditions: Post Ocular Surgical Inflammation and Pain

Summary: to evaluate the safety and efficacy of otx-dp as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.


Eligibility criteria:
inclusion criteria: * has a cataract and is expected to undergo clear corneal cataract surgery with phacoemulsification and implantation of a posterior chamber intraocular lens * has a potential post-operative pinhole corrected snellen va of at least 20/200 or better in both eyes exclusion criteria: * any intraocular inflammation in the study eye present during the screening slit lamp examination * score greater than "0" on the ocular pain assessment in the study eye at screening * any intraocular inflammation in the study eye present during the screening slit lamp examination
effectiveness of gelatamp in wound healing after teeth extraction: a randomized clinical trial

Conditions: Wound Heal

Summary: this study compares the effectiveness of gelatamp for intraoral wound closure after extraction of mandibular teeth.

in the interventional group, after extraction of mandibular teeth, the extraction socket will be augmented with gelatamp. then a gauze pack will be placed over it. in the control group, after extraction of mandibular teeth, a gauze pack will be placed over the socket.

Eligibility criteria:
inclusion criteria: * patients requiring extraction of mandibular teeth * healthy patients (asa i) or patients with mild systemic disease but no functional limitations (asa ii) * patients not allergic to the drugs or anesthetics used in the study. exclusion criteria: * patients taking medications that influences wound healing * smokers * uncooperative patients * patients requiring extraction of grade ii or iii mobile teeth * patients requiring surgical extraction of teeth.
combined effect of acitretin and narrow band ultraviolet b on vitiligo repigmentation

Conditions: Hyperlipidemias; Xerosis; Depression; Liver Diseases

Summary: since abnormal keratinocyte (kc) proliferation and differentiation as well as defective e cadherin expression were reported in vitiligo lesions, the investigators set to study the potential efficacy of combining retinoids, which are known to improve kc proliferation and differentiation and increase the expression of adhesion molecules, with narrowband uvb in the treatment of vitiligo.

• twenty patients with generalized vitiligo will be included in this study. all patients will be subjected to: * clinical evaluation: * an informed written consent. * history taking include age, previous treatment, disease activity * clinical examination including vitiligo area scoring index (vasi) and vitiligo disease activity score (vida) * photography (before starting the treatment and every 2 weeks till the end of the study) laboratory evaluation: * 2 mm punch skin biopsies will be taken from vitiligo patients, 1 from lesional and the other from perilesional skin before treatment. * the patients will be randomly assigned to two groups: group a: patients will receive three nb-uvb sessions per week for 48 sessions. group b: patients will receive three nb-uvb sessions per week for 48 sessions combined with acitretin in a dose of 0.3mg/kg/day daily. * controls: 20 individuals age and sex matched will be biopsied from the skin of their abdominoplasty surgery. * another two 2 mm punch skin biopsies will be taken from lesional and perilesional skin at the onset of repigmentation if repigmentation starts before completion of the 48 treatment session or after completion of the treatment period if repigmentation does not occur. * .all biopsies from patients and controls will be stained immunohistochemically by anti-e cadherin antibody.

Eligibility criteria:
inclusion criteria: * patients with generalized non-segmental vitiligo (25%-75%) * males, postmenopausal females and premenopausal females not planning to get pregnant during the period of treatment and after 2 years from the end of treatment. * age more than 18 years. exclusion criteria: * children ˂ 18 years old * pregnant females * premenopausal females planning to get pregnant within the period of treatment or within 2 years after. * patients receiving treatment for vitiligo within the past 2 months. * patients with abnormal liver profile * patients with abnormal lipid profile * patients with associated photosensitive disorders * patients having associated skin diseases other than vitiligo * cataract and aphakia * high cumulative dose from previous sessions of narrowband ˃ 200-300 session
implementation of apnoea test for patients with suspected brain death

Conditions: Brain Death

Summary: this study consists of a survey created for intensive care physicians regarding their current practice of the implementation of apnoea test for patients with suspected brain death.

although the apnoea test is part of nearly all protocols for determining brain death; implementation significantly differs among intensive care physicians according to national-level acts, national society protocols or local protocols. this cross-sectional study is based on an international, web-based questionnaire created for intensive care physicians, consisting of 25 questions in english. the survey will provide a current state of the practice of apnoea testing in patients with suspected brain death. the results can support the determination of future acts to standardize the apnoea test process. the given answers are anonymous. the e-mail address of the respondent is not recorded. answers are treated solely for scientific purposes.

Eligibility criteria:
inclusion criteria: * physicians working in intensive care units exclusion criteria: -

Keywords: brain death determination apnoea test survey
a study to find the best dose of su011248 when given with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors

Conditions: Neoplasms

Summary: this study will assess the maximum tolerated dose, overall safety and antitumor activity of su011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists. * patient has a good performance status (ecog 0 or 1). exclusion criteria: * prior treatment with either pemetrexed or su011248. * coughing up blood within 4 weeks before starting study treatment (small amounts okay). * hypertension that cannot be controlled by medications.

Keywords: solid tumor malignancy non-small cell lung cancer sunitinib pemetrexed phase 1 mesothelioma
change in choroidal thickness of myopic eyes with a myopia control contact lens

Conditions: Myopia

Summary: in this study, the direct effect of the misight contact lens (cooper vision), a daily disposable contact lens recently approved in germany for the treatment of myopia, will be investigated. the aim of this study is to demonstrate an increase in choroidal thickness due to the myopic defocus induced by the contact lens. the increase in choroidal thickness after 30 minutes of exposure to the myopic defocus induced by the contact lens will be demonstrated by measuring the subfoveal and macular choroidal thickness.

the increasing incidence of short-sightedness (myopia) worldwide has led to the development of various therapies to control axial length myopia. the latest developments include contact lenses to inhibit the growth of the bulb length, which should influence the growth of the eye in childhood and adolescence by inducing a myopic defocus in the periphery of the retina. in this study, the direct effect of the misight contact lens (cooper vision), a daily disposable contact lens recently approved in germany for the treatment of myopia, will be investigated. the aim of this study is to demonstrate an increase in choroidal thickness due to the myopic defocus induced by the contact lens. the increase in choroidal thickness after 30 minutes of exposure to the myopic defocus induced by the contact lens will be demonstrated by measuring the subfoveal and macular choroidal thickness. in addition, the influence of accommodation will be investigated by measuring the choroidal thickness after 30 minutes of activity at near and far distance. one eye of each of 8 healthy subjects with myopic refraction from -0.5 diopters in the spherical equivalent will be included, with laterality (right/left) being randomized. the choroidal thickness is measured using optical coherence tomography (oct), which is standard in clinical routine. the examination is non-invasive and is carried out at three points in time: the baseline measurement is carried out before inserting the contact lens, then after 30 minutes of exposure and near focusing. a further measurement is carried out within a week after a further 30 minutes of exposure and distance focusing, so that the results are not distorted by the previous near work. in addition, the axial length is determined at each of the 3 measurement times using optical biometry.

Eligibility criteria:
inclusion criteria: * myopic refraction * consent to participate * minimum age 18 years * full legal capacity exclusion criteria: * ocular disease affecting imaging quality including but not limited to cataract, keratoconus * ocular disease affecting choroidal thickness (pachychoroidal disease) * astigmatism greater than 1,5 diopters * best corrected distance visual acuity of 0,1 logmar or worse * status post eye surgery * status post treatment for myopia control

Keywords: myopia contact lens myopia progression
percutaneous coronary intervention before transcatheter aortic valve implantation

Conditions: Valvular Heart Disease; Aortic Valve Stenosis; Coronary Artery Disease

Summary: the aim of this trial is to evaluate the safety and cost effectiveness of omission of percutaneous coronary intervention of significant coronary artery disease in patients scheduled to undergo transcatheter aortic valve implantation.


Eligibility criteria:
inclusion criteria: * severe aos meeting the criteria stated by the esc in the esc/eacts guidelines for the management of valvular heart disease and considered symptomatic (nyha functional class ≥ 2); * tavi decided by multidisciplinary heart team taken into account the international standards by esc and guidelines of dutch society for cardiology (nvvc); * ≥ 1 stenosis in epicardial coronary artery (\> 2.5mm) or bypass graft. stenosis is considered significant if angiographic 70-99% or angiographic 40-70% with positive hemodynamic parameters. * written informed consent. exclusion criteria: * unprotected lm-stenosis or equivalent * no pci-eligible stenosis * contraindication for dapt * life expectancy \< 1 year

Keywords: transcatheter aortic valve implantation percutaneous coronary intervention
clinical performance assessment of a daily wear monthly replacement soft silicone hydrogel contact lens

Conditions: Refractive Errors

Summary: the purpose of this study is to obtain on-eye performance data to inform contact lens product development.

subjects are expected to attend 5 scheduled visits. the expected duration of subject participation in the study is approximately 60 days, with approximately 30 days (± 2 days) per product.

Eligibility criteria:
inclusion criteria: * sign informed consent document. * successful wear of spherical weekly/monthly soft contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months. * possess spectacles that provide a corrected visual acuity of 20/40 or better in both eyes. * other protocol-specified inclusion criteria may apply. exclusion criteria * any eye condition or disease or use of medication that contraindicates contact lens wear. * eye surgery, irregular cornea, eye injury as specified in the protocol. * routinely sleeps in contact lenses at least 1 night per week over the last 3 months prior to enrollment. * any use of topical ocular medications, artificial tear or rewetting drops that would require instillation during contact lens wear. * habitually wears biofinity contact lenses. * other protocol-specified exclusion criteria may apply.

Keywords: contact lenses
improving primary care after stroke (ipcas)

Conditions: Stroke

Summary: no formal primary care based model of care exists to support stroke survivors living in the community. a large variation in the range, quality and access to health services offered to stroke survivors between and within local clinical commissioning groups suggests that many of the stroke survivors' needs are not being met systematically. therefore, to address the longer term needs we have developed a multi-factorial primary care model that seeks to enable greater engagement with stroke care and community services, to link effectively to specialist services, and to improve the lives of stroke survivors. this will be a two-arm cluster randomised controlled trial. participating general practices will be randomised to deliver either the new model of stroke care or current usual care. the aim of this trial will be to assess the clinical and long-term cost effectiveness of the new model of primary care for stroke survivors living in the community. the primary outcome for the trial will be measured using two sub-scales (emotion and handicap) of the stroke impact scale questionnaire at 12 months.

the ipcas trial is a two-arm cluster randomised controlled trial with general practices as the unit of randomisation. the aim of this trial is to evaluate the clinical and long-term cost effectiveness of a novel model of primary care for stroke survivors living in the community. people with a history of stroke on the registers of gp practices in the east of england and the east midlands will be invited to take part. we will aim to recruit approximately 920 people registered with 46 general practices. we will target practices with a stroke register comprising a minimum of 100 patients, to ensure that we reach our cluster target of 16 - 24 participants. potentially eligible participants will be sent an invitation to take part in the study by their gp surgery. once all invitation letters and reminders have been sent out to patients in a practice, the gp practice will be randomised. gp practices will be randomised in a ratio of 1:1 to intervention or control. intervention practices will deliver the new model of primary care. the control arm will consist of current usual care. data collection will occur at baseline and at 6 and 12 months. this will comprise a combination of postal and telephone administered questionnaires and a review of general practice notes. the primary endpoint for the trial will be two sub-scales (emotion and handicap) of the stroke impact scale (sis v3.0) as co-primary outcomes at 12 months (adjusted for baseline). economic evaluation as well as quantitative and qualitative assessments of intervention fidelity will also be performed.

Eligibility criteria:
inclusion criteria: * on practice register with a history of stroke. * able to provide written informed consent (with or without the help of a carer). * age 18 years or older. exclusion criteria: * patients on the palliative care register. * patients living in a nursing home.
phase ii trial in elderly patients with aml or mds in complete remission not eligible for allogenic transplant

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Transplant-Related Hematologic Malignancy

Summary: flat-auto is a phase ii trial. fludarabine and ara-c will be combined with the alkylating agent treosulfan (flat), to investigate the feasibility and the efficacy of a new regimen, supported with autologous peripheral blood sct (pbsct), as final postremission consolidation in aml/mds elderly patients.


Eligibility criteria:
inclusion criteria: * pts with de novo or secondary aml or with int 2 or high risk mds according to ipss. * pts unable or unfit to receive sct from an hla (human leukocyte antigen)-identical related (sib) or unrelated (mud), or hla-haploidentical related (haplo) donor. * hematologic cr (appendix d) after 1 or 2 cycles of induction standard chemotherapy. * successful collection of autologous pbsc: ≥ 5.0x10e6 /kg patient bodyweight (bw) * age ≥ 65 years. * performance status 0-2 ecog (eastern cooperative oncology group), 60-100% karnofsky (appendix e). * written informed consent. exclusion criteria: * diagnosis of aml m3. * second concomitant malignancies. * severe concomitant illnesses/medical conditions (e.g. impaired respiratory and/or cardiac function). * known and manifested malignant involvement of the central nervous system (cns) * active infectious disease * hiv- positivity or active hepatitis infection * impaired liver function (bilirubin \> 1.5 x upper normal limit; transaminases \> 3.0 x upper normal limit) * impaired renal function (creatinine-clearance \ 1.5 x upper normal limit). * known hypersensitivity to treosulfan and/or cytarabine and/or fludarabine * participation in another experimental drug trial within 4 weeks before day -6 * non-cooperative behaviour or non-compliance * psychiatric diseases or conditions that might impair the ability to give informed consent
a nutrition and parenting program for fathers and their pre-school age children

Conditions: Pediatric Obesity

Summary: this pilot study evaluates the feasibility and impact of a father-focused childhood obesity prevention program on paternal food-related parenting practices, mealtime behaviors and father/child nutrition and physical activity behaviors. half of participants (low-income father and child dyads) will receive an intervention immediately while the other half of participants will serve as a wait-list control group and receive the intervention at a later date.

all participants (low-income father and child dyads) will receive an 8 session (2 hours/session) (dad) including community-based, hands-on, nutrition and parent education intervention with between-session technology enhancements. dyads will be randomly assigned within groups of 10 to dad or a wait-list control group (delay). assessments will be conducted at pre, post and 1 month post including a subset of data from cohabiting mothers to assess moderating influences on outcomes.

Eligibility criteria:
inclusion criteria: * "father" eligible for a federal food assistance or related program (e.g. snap) or living in an area with \>30% poverty * having at least one preschool age child (ages 3-5 years old) * at least 18 years of age and able to speak english exclusion criteria: * no presence or interaction with child during meal or snack times.

Keywords: fathers
study to evaluate the safety and pharmacokinetics of ckd-379

Conditions: Type II Diabetes Mellitus

Summary: a study to compare the pharmacokinetics and safety between ckd-379 and d759, d745, d029, d150 combination

a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of ckd-379 in healthy volunteers under fed conditions

Eligibility criteria:
inclusion criteria: * between 19 aged and 50 aged in healthy adult * 18.0kg/m2≤body mass index(bmi)≤27.0kg/m2 and 50.0kg≤body weight≤90.0kg exclusion criteria: * have clinical significant medical history or disease that blood, kidney(moderate nephropathy and etc.), endocrine system(type i or type ii diabetes mellitus, diabetic ketoacidosis, diabetic coma and etc.), respiratory system, gastrointestinal system, urinary system, cardiovascular system(heart failure, torsades de pointes and etc.), liver(moderate liver disorder and etc.), mental system, nervous system, immune system * have a gastrointestinal disease(crohn's disease, ulcer etc.) history that can effect drug absorption or surgery * those who are pregnant or breastfeeding * those who are deemed inappropriate to participate in clinical trial by investigators